There are 8 papers on Comorbidity-Polypharmacy Score in aging research: 8 observational studies in people.
8 papers study it4 more mention it13 findings
See all 12 papers on Comorbidity-Polypharmacy Score
“multiple linear regression analysis revealed that the CPS was independently associated with the BI efficiency (β = -0.100, 95% CI: -0.040, -0.029; P < 0.001)”
- Humans8
Interventions
4Walking outdoors
downin humans1OR 0.6
1 study
Walking outdoors
downin humans1OR 0.6
Walking outdoors are linked with lower Comorbidity-Polypharmacy Score in humans (age- and sex-adjusted) (OR 0.60, 95% CI 0.42-0.86).
Humansage- and sex-adjusted
Fruits
downin humans1OR 0.63
1 study
Fruits
downin humans1OR 0.63
Fruits are linked with lower Comorbidity-Polypharmacy Score in humans (adjusted for age, sex, body mass index, physical activity and cognitive status) (OR 0.63, 95% CI 0.41-0.97).
Humansadjusted for age, sex, body mass index, physical activity and cognitive status
Leafy green vegetables
downin humans1OR 0.54
1 study
Leafy green vegetables
downin humans1OR 0.54
Leafy green vegetables are linked with lower Comorbidity-Polypharmacy Score in humans (adjusted for age, sex, body mass index, physical activity and cognitive status) (OR 0.54, 95% CI 0.33-0.87).
Humansadjusted for age, sex, body mass index, physical activity and cognitive status
Cruciferous vegetables
downin humans1OR 0.56
1 study
Cruciferous vegetables
downin humans1OR 0.56
Cruciferous vegetables are linked with lower Comorbidity-Polypharmacy Score in humans (adjusted for age, sex, body mass index, physical activity and cognitive status) (OR 0.56, 95% CI 0.35-0.90).
Humansadjusted for age, sex, body mass index, physical activity and cognitive status
Effects
3Length of hospital stay
upin humans1
1 study
Length of hospital stay
upin humans1
Comorbidity-Polypharmacy Score is linked with higher length of hospital stay in humans (hip fracture undergoing surgery) (β = 0.047, 95% CI: 0.199, 0.366, P < 0.001).
Humanship fracture undergoing surgeryn = 11,564
Barthel Index efficiency
downin humans1
1 study
Barthel Index efficiency
downin humans1
Comorbidity-Polypharmacy Score is linked with lower Barthel Index efficiency in humans (hip fracture undergoing surgery) (β = -0.100, 95% CI: -0.040, -0.029, P < 0.001).
Humanship fracture undergoing surgeryn = 11,564
Mortality
no changein humans1
1 study
Mortality
no changein humans1
Comorbidity-Polypharmacy Score was not clearly linked with mortality in humans.
Humans
Associations
630-day mortality
upin humans1
1 study
30-day mortality
upin humans1
Comorbidity-Polypharmacy Score predicts 30-day mortality in humans (mixed ICU population) (AUROC 0.75 (95% CI 0.69 to 0.81)).
Humansmixed ICU population30-dayn = 319
Discharge to a long-term care facility
upin humans1
1 study
Discharge to a long-term care facility
upin humans1
Comorbidity-Polypharmacy Score predicts discharge to a long-term care facility in humans (traumatic injuries (ISS ≥ 9)) (aOR 1.60, 95% CI 1.10-2.32).
Humanstraumatic injuries (ISS ≥ 9)n = 4,522
Discharge to a rehabilitation facility
upin humans1
1 study
Discharge to a rehabilitation facility
upin humans1
Comorbidity-Polypharmacy Score predicts discharge to a rehabilitation facility in humans (traumatic injuries (ISS ≥ 9)) (aOR 1.72, 95% CI 1.43-2.07).
Humanstraumatic injuries (ISS ≥ 9)n = 4,522
Mortality
upin humans1
1 study
Mortality
upin humans1
Comorbidity-Polypharmacy Score is linked with a higher risk of mortality in humans (traumatic injuries (ISS ≥ 9)) (aOR 1.88; 95% CI 1.23-2.89).
Humanstraumatic injuries (ISS ≥ 9)n = 4,522
Age
upin humans1
1 study
Age
upin humans1
Age is associated with Comorbidity-Polypharmacy Score in humans (p < 0.001).
Humansn = 648
Overall survival
downin humans1HR 1.11
1 study
Overall survival
downin humans1HR 1.11
Comorbidity-Polypharmacy Score is associated with overall survival in humans (HPV-positive patients) (HR 1.11 in HPV-positive cohort; HR 1.05 in entire cohort (P=.05)).
HumansHPV-positive patientsn = 117